MTOR and non-small cell lung carcinoma: In another study, non-small cell lung cancer (NSCLC) cells designated as mesenchymal-like based on their molecular profile, were found to be more resistant than epithelial-like NSCLC cells to erlotinib and the PI3K/AKT/mTOR inhibitors GDC0941 and 8-aminoadenosine, but more sensitive to pemetrexed, paclitaxel and docetaxel [97].